Search results
Jun 1, 2023 · 1. Introduction. Peripheral arterial disease, PAD, usually caused by atherosclerosis, may imply engagement of any artery outside the heart and brain, but the term is most commonly used for lower limb disorder, e.g., asymptomatic lower limb PAD, intermittent claudication (IC) and chronic limb threatening ischemia (CLTI).
Jan 30, 2020 · Indeed, patients with PAD have an increased rate of ischemic stroke, myocardial infarction (MI), and cardiovascular death. 2–4 Furthermore, patients with coronary artery disease (CAD) and PAD have a much higher risk of cardiovascular mortality than CAD alone. 5,6 Importantly, PAD is a significant burden for patients in terms of quality of life and financial well-being. 7 PAD is a relatively ...
- Graham H. Bevan, Graham H. Bevan, Khendi T. White Solaru, Khendi T. White Solaru
- 2020
Mar 28, 2020 · (Funded by Bayer and Janssen Pharmaceuticals; VOYAGER PAD ClinicalTrials.gov number, NCT02504216.) ... This article was published on March 28, 2020, and updated on April 30, 2020, at NEJM.org. ...
- Marc P Bonaca, Rupert M Bauersachs, Sonia S Anand, E Sebastian Debus, Mark R Nehler, Manesh R Patel,...
- 2020
Dec 11, 2020 · December 2020: we reviewed our guidance on opioids for non-cancer pain in response to a Public Health England evidence review on dependence on, and withdrawal from, prescribed medicines. We added links in recommendation 1.6.7 to other NICE guidelines and resources that support discussion with patients about opioid prescribing, and safe withdrawal management.
Jun 30, 2020 · The sensitivity, specificity, and accuracy values computed at the PAD classification threshold levels identical to the labeling threshold values [note that (i) the deep CNN was calibrated to the true PAD severity as part of training, and (ii) a PAD severity level can be mapped to its corresponding ABI by using the polynomial regression model relating ABI to PAD severity in section ...
Aug 14, 2020 · Antiplatelet therapy is a mainstay of symptomatic peripheral artery disease (PAD) treatment. Low-dose aspirin reduces the risk of myocardial infarction and other cardiovascular events in this patient population. 1 The CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk for Ischemic Events), published in 1996, showed a 23.8% relative risk reduction in vascular events with clopidogrel ...
Apr 8, 2020 · Virtual Meeting – Two multinational trials are poised to alter standards of care in areas of antithrombotic therapy. Presented as latebreakers during the virtual ACC meeting, one trial, called VOYAGER PAD, associated a direct oral anticoagulant (DOAC) with improved outcomes after revascularization for peripheral artery disease (PAD). The other, called POPular TAVI, found oral anticoagulation ...
